- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-1 (IL-1) and the inflammasome in cancer
Authors
Keywords
IL-1β, NLRP3, Inflammasome, Cancer, Tumor microenvironment, Tumor-promoting inflammation
Journal
CYTOKINE
Volume 153, Issue -, Pages 155850
Publisher
Elsevier BV
Online
2022-03-10
DOI
10.1016/j.cyto.2022.155850
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies
- (2021) Patrick M. Reagan et al. JOURNAL OF CLINICAL ONCOLOGY
- Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design
- (2021) Pilar Garrido et al. Future Oncology
- NLRP3 inflammasome in cancer and metabolic diseases
- (2021) Bhesh Raj Sharma et al. NATURE IMMUNOLOGY
- 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
- (2021) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression
- (2021) Daniel Hofbauer et al. IMMUNITY
- Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.
- (2021) Ahmad Awada et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
- (2020) Shipra Das et al. CANCER RESEARCH
- Effects of Interleukin-1β Inhibition on Incident Anemia
- (2020) Mounica Vallurupalli et al. ANNALS OF INTERNAL MEDICINE
- Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) as monotherapy or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N.
- (2020) Tony S. K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
- (2020) Shaima’a Hamarsheh et al. Nature Communications
- The NLRP1 Inflammasome in Human Skin and Beyond
- (2020) Gabriele Fenini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
- (2020) Ting Zhou et al. NATURE
- Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
- (2020) Daniel B. Rubin et al. JAMA Neurology
- Inhibition of IL-1β by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial
- (2020) Connie C Wong et al. CANCER RESEARCH
- Inherited causes of clonal haematopoiesis in 97,691 whole genomes
- (2020) Alexander G. Bick et al. NATURE
- Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer
- (2020) Mingyi Ju et al. BRIEFINGS IN BIOINFORMATICS
- Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer
- (2019) Oxana Dmitrieva-Posocco et al. IMMUNITY
- The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer
- (2019) Hermann Gram PHARMACOLOGICAL RESEARCH
- Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma
- (2019) Timothy A Brighton et al. CLINICAL CANCER RESEARCH
- Commensal Microbiota Promote Lung Cancer Development via γδ T Cells
- (2019) Chengcheng Jin et al. CELL
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
- (2019) Mercedes Segovia et al. CANCER CELL
- NOD‐like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD
- (2019) Koichiro Ohashi et al. HEPATOLOGY
- Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
- (2019) Alberto Mantovani et al. IMMUNITY
- The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).
- (2019) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells
- (2019) Ping-Hsien Lee et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages
- (2019) Qi Chen et al. BRITISH JOURNAL OF CANCER
- Macrophages reprogrammed by lung cancer microparticles promote tumor development via release of IL-1β
- (2019) Jie Chen et al. Cellular & Molecular Immunology
- Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC
- (2019) Jian Huang et al. ONCOGENE
- Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
- (2018) Kyohei Nakamura et al. CANCER CELL
- CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular DiseaseNovelty and Significance
- (2018) Soichi Sano et al. CIRCULATION RESEARCH
- Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
- (2018) Marlies Meisel et al. NATURE
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
- (2018) Fabrizio De Benedetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
- (2018) Carlo Marchetti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
- (2018) Xiaoyuan Wang et al. Cell Death & Disease
- Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
- (2018) Hongbin He et al. Nature Communications
- Contribution of IL-1RI Signaling to Protection against Cryptococcus neoformans 52D in a Mouse Model of Infection
- (2018) Mitra Shourian et al. Frontiers in Immunology
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
- (2018) Valerio Gelfo et al. Cancers
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
- (2018) Uwe Platzbecker et al. BLOOD
- Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer
- (2018) Razelle Kurzrock et al. OncoImmunology
- Overview of the IL-1 family in innate inflammation and acquired immunity
- (2017) Charles A. Dinarello IMMUNOLOGICAL REVIEWS
- NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma
- (2017) Donnele Daley et al. JOURNAL OF EXPERIMENTAL MEDICINE
- S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β
- (2017) Benjamin Weichand et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- (2017) Paul M Ridker et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
- (2017) Tamas Hickish et al. LANCET ONCOLOGY
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma
- (2017) Z Zhai et al. ONCOGENE
- Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
- (2017) José J. Fuster et al. SCIENCE
- NLRP3 inflammasome activation plays a carcinogenic role through effector cytokine IL-18 in lymphoma
- (2017) Xia Zhao et al. Oncotarget
- Microbiota Normalization Reveals that Canonical Caspase-1 Activation Exacerbates Chemically Induced Intestinal Inflammation
- (2017) Adrian J. Błażejewski et al. Cell Reports
- CAR T Cells Releasing IL-18 Convert to T-Bet high FoxO1 low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
- (2017) Markus Chmielewski et al. Cell Reports
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
- (2017) Biliang Hu et al. Cell Reports
- Inflammasomes and Cancer
- (2017) Rajendra Karki et al. Cancer Immunology Research
- Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development
- (2017) Melvin Kantono et al. Frontiers in Immunology
- Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma
- (2016) John A. Lust et al. AMERICAN JOURNAL OF HEMATOLOGY
- Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial
- (2016) Jared E. Knickelbein et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- O-027A pivotal phase 3 trial of MABp1 in advanced colorectal cancer
- (2016) T. Hickish et al. ANNALS OF ONCOLOGY
- Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome
- (2016) Qianming Du et al. BIOCHEMICAL PHARMACOLOGY
- The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
- (2016) A. A. Basiorka et al. BLOOD
- Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation
- (2016) Franklin L. Zhong et al. CELL
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- Blocking NF- B Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
- (2016) X. Guo et al. CLINICAL CANCER RESEARCH
- Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
- (2016) Xing Liu et al. NATURE
- Mechanism and Regulation of NLRP3 Inflammasome Activation
- (2016) Yuan He et al. TRENDS IN BIOCHEMICAL SCIENCES
- Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
- (2016) Aditya Stanam et al. Oncotarget
- IL-1 drives breast cancer growth and bone metastasis in vivo
- (2016) Ingunn Holen et al. Oncotarget
- Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression
- (2016) Ruihua Ma et al. OncoImmunology
- Aspirin for Cancer Prevention
- (2016) Eduardo Vilar et al. JAMA Oncology
- Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer
- (2016) Yin Cao et al. JAMA Oncology
- The Q705K and F359L Single-Nucleotide Polymorphisms of NOD-Like Receptor Signaling Pathway: Association with Chronic Pancreatitis, Pancreatic Cancer, and Periodontitis
- (2015) Andrzej Miskiewicz et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells
- (2015) A. T. Koch et al. CANCER RESEARCH
- Regulation of inflammasome activation
- (2015) Si Ming Man et al. IMMUNOLOGICAL REVIEWS
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
- (2015) David S. Hong et al. INVESTIGATIONAL NEW DRUGS
- Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
- (2015) Qian Zhang et al. NATURE
- Expression of IL-1α correlates with distant metastasis in patients with head and neck squamous cell carcinoma
- (2015) Xavier León et al. Oncotarget
- Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
- (2015) Ole Audun Werner Haabeth et al. OncoImmunology
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Inflammasome Priming by Lipopolysaccharide Is Dependent upon ERK Signaling and Proteasome Function
- (2014) M. G. Ghonime et al. JOURNAL OF IMMUNOLOGY
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells
- (2014) Frédérique Végran et al. NATURE IMMUNOLOGY
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The NOD-Like Receptor Signalling Pathway in Helicobacter pylori Infection and Related Gastric Cancer: A Case-Control Study and Gene Expression Analyses
- (2014) Natalia Castaño-Rodríguez et al. PLoS One
- Th17 Cells in Cancer: The Ultimate Identity Crisis
- (2014) Stefanie R. Bailey et al. Frontiers in Immunology
- Obesity Promotes Breast Cancer by CCL2-Mediated Macrophage Recruitment and Angiogenesis
- (2013) L. M. Arendt et al. CANCER RESEARCH
- TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells
- (2013) Hongliang Fang et al. Cellular & Molecular Immunology
- IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells
- (2013) Shlomo Z. Ben-Sasson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: TLR Signaling Licenses IRAK1 for Rapid Activation of the NLRP3 Inflammasome
- (2013) T. Fernandes-Alnemri et al. JOURNAL OF IMMUNOLOGY
- The Role of IL-1 in the Early Tumor Cell-Induced Angiogenic Response
- (2013) Y. Carmi et al. JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- PAMPs and DAMPs: signal 0s that spur autophagy and immunity
- (2012) Daolin Tang et al. IMMUNOLOGICAL REVIEWS
- Non-transcriptional Priming and Deubiquitination Regulate NLRP3 Inflammasome Activation
- (2012) Christine Juliana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Th9 cells promote antitumor immune responses in vivo
- (2012) Yong Lu et al. JOURNAL OF CLINICAL INVESTIGATION
- Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity
- (2012) Bénédicte F. Py et al. MOLECULAR CELL
- Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
- (2012) Rahul Purwar et al. NATURE MEDICINE
- Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma
- (2012) Deepti Verma et al. Pigment Cell & Melanoma Research
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
- (2011) C. A. Dinarello BLOOD
- IL-18 Induces PD-1-Dependent Immunosuppression in Cancer
- (2011) M. Terme et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The bottleneck of JNK signaling: Molecular and functional characteristics of MKK4 and MKK7
- (2011) Wiebke Haeusgen et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- The Role of Plasmacytoma Growth Factor in the in Vitro Responses of Murine Plasmacytoma Cells
- (2010) RICHARD P. NORDAN et al. Annals of the New York Academy of Sciences
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis
- (2010) Md. Hasan Zaki et al. IMMUNITY
- The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer
- (2010) Irving C. Allen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4
- (2010) B. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
- (2009) Ahmad A. Tarhini et al. CANCER
- Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis
- (2009) I Ikonomidis et al. HEART
- Critical Regulation of Early Th17 Cell Differentiation by Interleukin-1 Signaling
- (2009) Yeonseok Chung et al. IMMUNITY
- The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress
- (2009) Luke A. J. O'Neill IMMUNOLOGICAL REVIEWS
- Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1β
- (2009) Miyako Okamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cutting Edge: TNF- Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial Stimulation
- (2009) L. Franchi et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: NF- B Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression
- (2009) F. G. Bauernfeind et al. JOURNAL OF IMMUNOLOGY
- Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
- (2009) John A. Lust et al. MAYO CLINIC PROCEEDINGS
- Pyroptosis: host cell death and inflammation
- (2009) Tessa Bergsbaken et al. NATURE REVIEWS MICROBIOLOGY
- Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice
- (2008) Shuiping Tu et al. CANCER CELL
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset
- (2008) Marc Veldhoen et al. NATURE IMMUNOLOGY
- IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells
- (2008) Valérie Dardalhon et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started